Axsome Therapeutics

Historical price data

Founded in 2012 by Dr. Herriot Tabuteau, Axsome Therapeutics has evolved from a development-stage company to a commercial leader in CNS therapeutics. The company's differentiated approach focuses on novel mechanisms of action for conditions with limited treatment options, resulting in three FDA-approved products and a robust pipeline. With a strong intellectual property portfolio extending through 2040 and multiple Phase 3 programs underway, Axsome is well-positioned to expand its leadership in the CNS therapeutic space.

Axsome develops novel CNS therapies through innovative drug combinations and proprietary formulations that enhance therapeutic benefits while maintaining strong intellectual property protection. Their platform focuses on identifying synergistic combinations of established compounds with novel mechanisms of action for underserved CNS conditions.

36 drugs in pipeline, 23 in Phase 3

Axsome competes in the CNS market against major pharmaceutical companies including Johnson & Johnson in depression, various migraine-focused companies, and sleep disorder specialists. However, the company's novel mechanisms of action and combination therapy approaches provide differentiation from standard treatments, allowing them to establish market presence despite established competition.